Two malaria vaccines are recommended by WHO for programmatic use in children living in P. falciparum malaria–endemic areas: RTS,S/AS01 (Mosquirix) and R21/Matrix-M. Go to footnote 1 Both vaccines have WHO prequalification. Go to footnote 2, Go to footnote 3, Go to footnote 4
Detailed information on the available products can be found in the vaccine comparison table, including licensing, presentation, formulation, dosage and route of administration. Go to footnote 5
The malaria vaccination series for each child should be completed with the same product whenever feasible. However, if the product used for a prior dose is unavailable or unknown, the series should be completed with either of the available WHO-recommended malaria vaccines. Restarting the vaccine series is not recommended. Go to footnote 6
- Go back to footnote reference 1
World Health Organization (2024). Malaria vaccines: WHO position paper, May 2024. Wkly Epidemiol Rec. 99(19):225–248 (https://www.who.int/publications/i/item/who-wer-9919-225-248, accessed 13 May 2026).
- Go back to footnote reference 2
World Health Organization (2026). RTS,S/AS01 (Mosquirix) (https://extranet.who.int/prequal/vaccines/p/mosquirix
, accessed 13 May 2026). - Go back to footnote reference 3
World Health Organization (2026). R21/Matrix-M liquid one-dose vial (https://extranet.who.int/prequal/vaccines/p/r21-malaria, accessed 13 May 2026).
- Go back to footnote reference 4
World Health Organization (2026). R21/Matrix-M liquid two-dose vial (https://extranet.who.int/prequal/vaccines/p/cyvac, accessed 13 May 2026).
- Go back to footnote reference 5
For specific product characteristics see the comparison table
- Go back to footnote reference 6
World Health Organization (2024). Malaria vaccines: WHO position paper, May 2024. Wkly Epidemiol Rec. 99(19):225–248 (https://www.who.int/publications/i/item/who-wer-9919-225-248, accessed 13 May 2026).
